{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:27:43Z","timestamp":1769261263003,"version":"3.49.0"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We report the case of a 77-year-old woman with metastatic gallbladder cancer who initially received adjuvant capecitabine following surgery. During this period, she developed a facial rash, associated with a positive antinuclear antibody (ANA) with a titer of 1:320. Six months later, disease recurrence prompted treatment with gemcitabine, cisplatin, and durvalumab. Shortly after completing six cycles of chemo-immunotherapy, she presented with rapidly progressive dyspnea, severe hypertension, thrombotic microangiopathy (TMA; confirmed on renal pathology), and multiorgan dysfunction, including hepatic and muscular involvement. Laboratory workup revealed a strongly positive ANA titer (1:1280) corresponding to strongly positive anti-Th\/To antibodies. Although the clinical presentation was highly suggestive of scleroderma renal crisis (SRC), it remained challenging to determine whether this was an immune-related adverse event, a paraneoplastic manifestation, or an exacerbation of a pre-existing autoimmune condition. This case illustrates the diagnostic and therapeutic complexity of autoimmune phenomena in oncology and highlights the importance of thorough autoimmune screening and multidisciplinary collaboration before and during immunotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2025.1658621","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:16:53Z","timestamp":1760329013000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case report of malignant hypertension and multiorgan dysfunction during immunotherapy for gallbladder cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Caroline","family":"Anthon","sequence":"first","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Pierret","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Houssiau","sequence":"additional","affiliation":[{"name":"Department of Rhumatology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selda","family":"Aydin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"De Cuyper","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Van Marcke","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Van Den Eynde","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Mazzeo","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Cornelis","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Galot","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois P.","family":"Duhoux","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Baurain","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Seront","sequence":"additional","affiliation":[{"name":"Institut Roi Albert II, Medical Oncology, Cliniques Universitaires Saint-Luc","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin Exp Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113022","article-title":"Anti-th\/to antibodies in scleroderma: good prognosis or serious concern","volume":"13","author":"Mo\u017cd\u017can","year":"2024","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000711","article-title":"Management of systemic sclerosis: the first five years","volume":"32","author":"Roofeh","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.018","article-title":"Anti\u2013programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study","volume":"160","author":"Panhaleux","year":"2022","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152460","article-title":"Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis","volume":"67","author":"Wallwork","year":"2024","journal-title":"Semin Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2023","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40801-023-00399-7","article-title":"Immune checkpoint inhibitors and scleroderma: data from the european pharmacovigilance database","volume":"11","author":"Nicoletti","year":"2024","journal-title":"Drugs  Real World Outcomes"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1771057","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1658621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:40:28Z","timestamp":1769092828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1658621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":11,"alternative-id":["10.3389\/fonc.2025.1658621"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1658621","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1658621"}}